Latest News
- Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
MedGenome Secures INR 400 Crore in Series E Round to Expand Genomics Access in Emerging Markets
With this latest funding, MedGenome aims to strengthen its integrated diagnostics offerings, improve accessibility, and continue spearheading genomics-led healthcare innovation at scale.
- By Newsdesk
- Bengaluru
- Jul 21, 2025
Genomic diagnostics leader MedGenome has raised $47.5 million (over ₹400 crore) in its latest Series E funding round, marking a significant milestone in its mission to democratize access to advanced genetic testing across India and other emerging markets.
The round was co-led by Denmark-based private equity firm Maj Invest, along with existing investors Novo Holdings and Sofina. The capital infusion will be used to accelerate MedGenome’s expansion plans, deepening its footprint in underserved regions where affordable, high-quality diagnostics remain a critical gap.
Founded in 2013, MedGenome currently offers more than 1,300 genetic tests and partners with over 6,000 hospitals, covering nearly 400 regions across the country. The company has emerged as a key player in enabling precision healthcare through its science-first approach and cutting-edge genomics technology.
“MedGenome stands out as a science-led platform with strong fundamentals, and this investment aligns with our conviction in the growing importance of genomics and personalised healthcare across emerging markets,” said Dr. Amit Kakar, Managing Partner and Head of Asia at Novo Holdings.
Jannick Dam Mortensen, Partner at Maj Invest Minorities, added, “With its robust genomics portfolio, MedGenome has consistently demonstrated its ability to drive innovation and precision diagnostics. We’re proud to support their next phase of growth as they expand their solutions across India and globally.”
With this latest funding, MedGenome aims to strengthen its integrated diagnostics offerings, improve accessibility, and continue spearheading genomics-led healthcare innovation at scale.